• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Pharma industry news


Genocea’s GEN-003 in prime position to lead genital herpes vaccine space, says GlobalData Analyst

30 April 2015

Genocea's GEN-003 is better positioned to compete in the future genital herpes treatment space, despite being slightly behind Agenus’ HerpV in development...


WHO coordinating the health response to Nepal earthquake and working to prevent spread of disease

30 April 2015

WHO has taken leadership in coordinating medical relief for communities affected by Saturday's devastating earthquake in Nepal...

Professor Alan Boyd

Professor Alan Boyd elected President of the Faculty of Pharmaceutical Medicine

30 April 2015

Professor Alan Boyd, owner of Boyds consultancy business, has been elected as President of the Faculty of Pharmaceutical Medicine...


Xtandi to drive prostate cancer treatment market value to $8.2 Billion by 2023

30 April 2015

The market value for prostate cancer will expand more than threefold to an estimated $8.2 billion by 2023, driven by the label extension of Xtandi...


Martindale Pharma expands international business in Asia Pacific

30 April 2015

Martindale Pharma today announced the appointment of AFT Pharmaceuticals as its distribution partner for several Asia Pacific markets...


ESCMID announces late-breaking study results at ECCMID

30 April 2015

The European Society of Clinical Microbiology and Infectious Disease announced a live update on breaking science emerging at its annual congress, ECCMID...


FDA to review Amgen’s Repatha as a treatment for high cholesterol

30 April 2015

The FDA will review data supporting Amgen’s Biologics License Application (BLA) for Repatha (evolocumab) for the treatment of high cholesterol...


CoLucid Pharmaceuticals announces initiation of first Phase 3 pivotal trial of lasmiditan in migraine

30 April 2015

CoLucid Pharmaceuticals has announced that the first patient has been randomised in its SAMURAI study, the Company’s Phase 3 pivotal trial of lasmiditan...


FDA accepts supplemental Biologics License Application for Opdivo in patients with previously untreated advanced melanoma

30 April 2015

The FDA has accepted for filing and review the sBLA for Opdivo for the treatment of previously untreated patients with unresectable or metastatic melanoma...


amp biosimilars AG appoints Rolf G. Werner as Chairman of the Scientific Board

29 April 2015

amp biosimilars has announced Professor Dr Rolf G. Werner is to head up the Scientific Board as "Chairman of the Scientific Board", effective immediately...


FDA grants fast track designation to Genzyme’s investigational substrate reduction therapy for the treatment of Fabry disease

29 April 2015

The FDA has granted Fast Track designation for the development of Genzyme’s GZ/SAR402671, an investigational substrate reduction therapy for Fabry disease...


Merck announces publication of pivotal data from Phase 3 clinical studies of Zerbaxa

29 April 2015

Results from Phase 3 clinical studies of Zerbaxa in complicated urinary tract infections and complicated intra-abdominal infections have been published...